stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Return on invested capital
Vericel Corporation's return on invested capital over the twelve months to 30 September 2026 was 7.88%, up 4.7 percentage points from fiscal 2025 (3.18%). Over the past ten years it has ranged from −138.0% (fiscal 2015) to 3.18% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 3.18% | 1.47 |
| FY2024 | 1.71% | 5.81 |
| FY2023 | −4.10% | 10.56 |
| FY2022 | −14.7% | (7.34) |
| FY2021 | −7.32% | (9.86) |
| FY2020 | 2.54% | 19.54 |
| FY2019 | −17.0% | (4.35) |
| FY2018 | −12.7% | 59.86 |
| FY2017 | −72.5% | 29.19 |
| FY2016 | −101.7% | 36.32 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ADMA ADMA Biologics Inc compare | 48.0% |
| AUPH Aurinia Pharmaceuticals Inc compare | 43.0% |
| VCEL Vericel Corporation | 7.88% |
| CLDX Celldex Therapeutics, Inc. compare | 0.00% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| PVLA Palvella Therapeutics, Inc. compare | 0.00% |
| IMNM Immunome, Inc. compare | −3,323.0% |
| BHVN Biohaven Ltd. compare | −6,659.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement